Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: Results of a preliminary study

Prostate Cancer and Prostatic Diseases

Volumn 11, Issue 2, 2008, Pages 181-186

  Paparel, P ^a,b   Chapelon, J Y ^b   Bissery, A ^c   Chesnais, S ^b   Curiel, L ^b   Gelet, A ^b,d  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b INSERM   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HIGH INTENSITY FOCUSED ULTRASOUND; LINEAR REGRESSION ANALYSIS; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RAT; SINGLE DRUG DOSE; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; INJECTIONS, INTRAPERITONEAL; MALE; MODELS, BIOLOGICAL; NEOADJUVANT THERAPY; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RATS; TAXOIDS; TUMOR BURDEN; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 43549084198     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4501005     Document Type: Article

References (23)

1. Colombel M, Gelet A. Principles and results of high-intensity focused ultrasound for localized prostate cancer. Prostate Cancer Prostatic Dis 2004; 7: 289-294.
2. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lasne Y, Lyonnet D et al Transrectal high-intensity focused ultrasound: Minimally invasive therapy of localized prostate cancer. J Endourol 2000; 14: 519-528.
3. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: Preliminary results. J Urol 1999; 161: 156-162.
4. Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004; 63: 297-300.
5. Paparel P, Curiel L, Chesnais S, Ecochard R, Chapelon JY, Gelet A. Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int 2005; 95: 881-885.
6. Moore WE, Lopez RM, Matthews DE, Sheets PW, Etchison MR, Hurwitz AS et al. Evaluation of high-intensity therapeutic ultrasound irradiation in the treatment of experimental hepatoma. J Pediatr Surg 1989; 24: 30-33.
7. Yang R, Reilly CR, Rescorla FJ, Sanghvi NT, Fry FJ, Franklin Jr TD et al. Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma. J Pediatr Surg 1992; 27: 246-250.
8. Yang R, Reilly CR, Rescorla FJ, Faught PR, Sanghvi NT, Fry FJ et al High-intensity focused ultrasound in the treatment of experimental liver cancer. Arch Surg 1991; 126: 1002-1009.
9. Fry FJ, Johnson LK. Tumor irradiation with intense ultrasound. Ultrasound Med Biol 1978; 4: 337-341.
10. Yu T, Huang X, Hu K, Bai J, Wang Z. Treatment of transplanted adriamycin-resistant ovarian cancers in mice by combination of adriamycin and ultrasound exposure. Ultrason Sonochem 2004; 11 287-291.
11. Frenkel V, Li KC. Potential role of pulsed-high intensity focused ultrasound in gene therapy. Future Oncol 2006; 2: 111-119.
12. Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 2002; 49: 499-503.
13. Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A. In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 1992; 52: 6353-6357.
14. Paparel P, Chapelon JY, Curiel L, Rabilloud M, Chesnais S, Gelet A. Potentiation of focal ultrasound treatment of prostate adenocarcinoma by concomitant chemotherapy with estramustine phosphate and paclitaxel. Prog Urol 2004; 14: 40-46.
15. Oudard S, Legrier ME, Boye K, Bras-Goncalves R, De Pinieux G, De Cremoux P et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169: 1729-1734.
16. Lokeshwar BL, Ferrell SM, Block NL. Enhancement of radiation response of prostatic carcinoma by taxol: Therapeutic potential for late-stage malignancy. Anticancer Res 1995; 15: 93-98.
17. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
18. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
19. Pitt WG, Husseini GA, Staples BJ. Ultrasonic drug delivery - a general review. Expert Opin Drug Deliv 2004; 1: 37-56.
20. Knox JD, Mitchel RE, Brown DL. Effects of hyperthermia on microtubule organization and cytolytic activity of murine cytotoxic T lymphocytes. Exp Cell Res 1991; 194: 275-283.
21. Yumita N, Umemura S. Sonodynamic antitumour effect of chloroaluminum phthalocyanine tetrasulfonate on murine solid tumour. J Pharm Pharmacol 2004; 56: 85-90.
22. Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003; 10: 463-468.
23. Mohamed F, Stuart OA, Glehen O, Urano M, Sugarbaker PH. Docetaxel and hyperthermia: Factors that modify thermal enhancement. J Surg Oncol 2004; 88: 14-20.